Ingrezza’s effects on chorea become stronger over time: Trial analysis
The effects of Ingrezza (valbenazine) on Huntington’s disease-associated chorea grew increasingly stronger over the course of the three-month Phase 3 KINECT-HD clinical trial, according to a post-hoc analysis. A post-hoc analysis is one planned and conducted after the trial has been completed. “This post-hoc analysis of the…